ANTX vs RXT
ANTX: AN2 Therapeutics leverages a proprietary boron chemistry platform to develop small-molecule drugs for neglected infectious diseases, blood cancers, and other high-unmet-need conditions. RXT: Rackspace Technology is a hybrid cloud and AI solutions operator serving enterprises that need governed, regulated infrastructure across private clouds, hyperscalers, and on-premises environments.
Side-by-side fundamentals
| Metric | ANTX | RXT | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $6.08 | $4.82 | |
| Market cap as of 2026-08-07 | $219M | $1.2B | |
| Net margin as of 2026-08-07 | n/a | -5.4% | |
| Gross margin as of 2026-08-07 | n/a | +18.5% | |
| Operating margin as of 2026-08-07 | n/a | -0.9% | |
| ROE as of 2026-08-07 | -52.3% | -363.6% | ANTX higher |
| ROA as of 2026-08-07 | -47.3% | -5.2% | RXT higher |
| Debt / equity as of 2026-08-07 | 0.00 | 114.82 | ANTX lower |
| Revenue growth (YoY) as of 2026-08-07 | n/a | -0.5% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -4.9% | |
| Beta as of 2026-08-07 | -1.00 | 3.16 | |
| 1-year return as of 2026-08-06 close | +465.6% | +295.1% | ANTX higher |
Fundamentals: market data, as of 2026-08-07. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.